MorphoSys AG Total Assets 2018-2021 | MOR

MorphoSys AG total assets from 2018 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
MorphoSys AG Annual Total Assets
(Millions of US $)
2020 $1,896
2019 $556
2018 $636
2017 $470
MorphoSys AG Quarterly Total Assets
(Millions of US $)
2021-09-30 $3,401
2021-06-30 $1,901
2021-03-31 $1,989
2020-12-31 $1,896
2020-09-30 $1,613
2020-06-30 $1,568
2020-03-31 $1,473
2019-12-31 $556
2019-09-30 $602
2019-06-30 $626
2019-03-31 $632
2018-12-31 $636
2018-09-30 $673
2018-06-30 $653
2018-03-31 $482
2017-12-31 $470
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.116B $0.374B
MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75